Intellia Therapeutics Announces Third Quarter 2026 Financial Results
Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ
How this was made
The 30-second read
Why it matters
The earnings release introduces fresh guidance and financial metrics that were not previously public, likely influencing short‑term price action.
Market read
First‑time disclosure of Q3 results provides material new information for traders, especially those focused on biotech and CRISPR pipelines.
What to watch
The new term loan facility provides additional financial flexibility that may support near‑term launch readiness.
Intellia reported lower collaboration revenue and a wider net loss in the third quarter, while advancing lonvo-z toward a March 10, 2027 PDUFA date, completing MAGNITUDE-2 enrollment and maintaining a cash runway expected at least into 2028.
R&D expense declined and the company advanced key regulatory and clinical milestones, but collaboration revenue declined, G&A expense increased and net loss widened versus the prior-year quarter.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended September 30, 2026 (amounts in thousands)GAAP | $7.16M | – | – |
| Research and development expense, three months ended September 30, 2026 (amounts in thousands)GAAP | 83.35M | – | – |
| General and administrative expense, three months ended September 30, 2026 (amounts in thousands)GAAP | 46.14M | – | – |
| Total operating expenses, three months ended September 30, 2026 (amounts in thousands)GAAP | 129.5M | – | – |
| Operating loss, three months ended September 30, 2026 (amounts in thousands)GAAP | −122.3M | – | – |
| Interest income and other, net, three months ended September 30, 2026 (amounts in thousands)GAAP | 5.84M | – | – |
| Interest expense, three months ended September 30, 2026 (amounts in thousands)GAAP | −611K | – | – |
| Change in fair value of investments, net, three months ended September 30, 2026 (amounts in thousands)GAAP | −10.39M | – | – |
| Total other (expense) income, net, three months ended September 30, 2026 (amounts in thousands)GAAP | −5.16M | – | – |
| Net loss, three months ended September 30, 2026 (amounts in thousands)GAAP | −$127.5M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.91 ) | – | – |
| Weighted average shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 140,186 | – | – |
| Stock-based compensation expense included in R&D expenses, third quarter of 2026GAAP | $7.4M | – | – |
| Stock-based compensation expense included in G&A expenses, third quarter of 2026GAAP | $7M | – | – |
| Collaboration revenue, nine months ended September 30, 2026 (amounts in thousands)GAAP | $29.87M | – | – |
| Research and development expense, nine months ended September 30, 2026 (amounts in thousands)GAAP | 246.7M | – | – |
| General and administrative expense, nine months ended September 30, 2026 (amounts in thousands)GAAP | 118.8M | – | – |
| Total operating expenses, nine months ended September 30, 2026 (amounts in thousands)GAAP | 365.5M | – | – |
| Operating loss, nine months ended September 30, 2026 (amounts in thousands)GAAP | −335.6M | – | – |
| Interest income and other, net, nine months ended September 30, 2026 (amounts in thousands)GAAP | 16.84M | – | – |
| Interest expense, nine months ended September 30, 2026 (amounts in thousands)GAAP | −611K | – | – |
| Change in fair value of investments, net, nine months ended September 30, 2026 (amounts in thousands)GAAP | −10.96M | – | – |
| Total other (expense) income, net, nine months ended September 30, 2026 (amounts in thousands)GAAP | 5.27M | – | – |
| Net loss, nine months ended September 30, 2026 (amounts in thousands)GAAP | −$330.4M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $ (2.53 ) | – | – |
| Weighted average shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 130,802 | – | – |
| Cash, cash equivalents and marketable securities as of September 30, 2026 (amounts in thousands)GAAP | $614.8M | – | – |
| Total assets as of September 30, 2026 (amounts in thousands)GAAP | 902.6M | – | – |
| Total liabilities as of September 30, 2026 (amounts in thousands)GAAP | 289.5M | – | – |
| Total stockholders’ equity as of September 30, 2026 (amounts in thousands)GAAP | 613.1M | – | – |
At least into 2028 outlook
- NoteThe company’s existing cash resources are expected to fund its operations at least into 2028 and well beyond lonvo-z’s anticipated U.S. approval and commercial launch in HAE in the first quarter of 2027.
- NoteThis guidance excludes all potential commercial revenues from lonvo-z and potential future funding from the company’s term loan facility.
What drove it
- Collaboration revenue decreased primarily due to a reduction in revenue from Regeneron.
- R&D expense decreased primarily due to lower external costs related to lonvo-z, lower stock-based compensation and lower research materials and contracted services costs, partially offset by higher headcount-related expenses.
- G&A expense increased primarily due to consulting costs associated with continued buildout of commercial infrastructure and higher legal, facility-related and compensation expenses.
- The company completed enrollment in MAGNITUDE-2, exceeding its targeted randomization of 60 patients, and reported significant progress advancing enrollment in MAGNITUDE.
- FDA accepted the lonvo-z BLA, granted Priority Review and set a PDUFA target action date of March 10, 2027.
Concerns
- Collaboration revenue was $7.2 million for the third quarter of 2026, compared to $13.8 million for the third quarter of 2025.
- G&A expenses were $46.1 million for the third quarter of 2026, compared to $30.5 million for the third quarter of 2025, reflecting commercial-infrastructure buildout and higher legal, facility-related and compensation expenses.
- Net loss was $127.5 million for the third quarter of 2026, compared to $101.3 million for the third quarter of 2025.
- Net loss for the third quarter of 2026 included an unrealized loss of $10.4 million due to changes in the fair value of investments.
- The cash-runway guidance excludes potential commercial revenues from lonvo-z and potential future funding from the term loan facility.
What to watch
- The March 10, 2027 PDUFA target action date for lonvo-z.
- Completion of lonvo-z commercial readiness efforts and the planned commercial launch in the first quarter of 2027.
- New lonvo-z patient perspectives and Phase 1/2 durability data planned for the November 12 investor webcast and ACAAI 2026 presentations.
- Enrollment progress in the MAGNITUDE Phase 3 trial in ATTR-CM following completed enrollment in MAGNITUDE-2.
- The impact of the up to $400 million OrbiMed term loan facility on financial and operational flexibility.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $614.8 million as of September 30, 2026, compared to $605.1 million as of December 31, 2025.
- In September, Intellia entered into a non-dilutive senior secured term loan facility with OrbiMed for up to $400 million.
- Total assets were 902,560 (amounts in thousands) as of September 30, 2026.
- Total liabilities were 289,471 (amounts in thousands) as of September 30, 2026.
- Total stockholders’ equity was 613,089 (amounts in thousands) as of September 30, 2026.
Analysis
Third-quarter collaboration revenue was $7.2 million, compared to $13.8 million in the third quarter of 2025, with the decline primarily attributed to lower revenue from Regeneron. The company remained a development-stage business, reporting a net loss of $127.5 million versus $101.3 million in the prior-year quarter. The current-quarter net loss included an unrealized loss of $10.4 million from changes in the fair value of investments, while the prior-year quarter included an unrealized gain of $3.4 million.
Operating spending reflected a mix of lower development costs and higher commercialization spending. R&D expense was $83.3 million compared to $94.7 million, driven by lower lonvo-z external costs, lower stock-based compensation and lower research materials and contracted services costs, partly offset by higher headcount-related expenses. G&A expense was $46.1 million compared to $30.5 million, as Intellia continued building commercial infrastructure and incurred higher consulting, legal, facility-related and compensation expenses.
The principal operating milestones centered on lonvo-z and nex-z. FDA accepted the lonvo-z BLA, granted Priority Review and set March 10, 2027 as the PDUFA target action date; FDA also advised that it was not currently planning an advisory committee. Intellia completed deployment of its field organization and expanded engagement with HAE treatment centers and payers ahead of a planned first-quarter 2027 launch. For nex-z, the company completed enrollment in MAGNITUDE-2, exceeding the targeted randomization of 60 patients, while reporting significant progress in MAGNITUDE enrollment.
Liquidity was $614.8 million in cash, cash equivalents and marketable securities as of September 30, 2026, compared with $605.1 million as of December 31, 2025. Management expects existing cash resources to fund operations at least into 2028 and well beyond the anticipated lonvo-z U.S. approval and commercial launch, excluding potential lonvo-z commercial revenue and potential future funding from the term loan facility. The September OrbiMed senior secured term loan facility, for up to $400 million, is intended to provide additional financial and operational flexibility as the company approaches regulatory and launch milestones.
Management, verbatim
This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead.
John Leonard, M.D., Intellia President and Chief Executive Officer
Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.
John Leonard, M.D., Intellia President and Chief Executive Officer
Not in the filing
stated, not guessed- Total revenue beyond reported collaboration revenue
- Reportable segment revenue and segment profitability
- Gross profit and gross margin
- Non-GAAP financial measures, including non-GAAP operating income, non-GAAP net income and non-GAAP EPS
- Prior-quarter values and sequential comparisons for reported income-statement metrics
- Operating cash flow
- Free cash flow
- Cash used in operations
- Capital expenditures
- Debt outstanding and borrowings under the OrbiMed term loan facility
- Share repurchases, dividends and other capital returns
- Forward revenue, gross margin, operating-expense or tax-rate guidance
- Prior-period outlook for comparison with actual results
- Additional executive quotes or CFO commentary
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Intellia Therapeutics announced its Q3 2026 financial results, including cash position, R&D and G&A expenses, net loss, and updates on its CRISPR programs lonvo‑z and nex‑z.
Ticker impact
Intellia Therapeutics filed its 8‑K reporting Q3 2026 results, cash balance, R&D spend and guidance to fund operations into 2028.
likely downside as investors digest higher cash burn and reduced collaboration revenue
New financial figures and guidance are disclosed for the first time, providing fresh data that can move the share price.
Market effects
Biotech sector may see heightened scrutiny on cash burn and partnership revenue trends.
US biotech investors may adjust exposure ahead of upcoming FDA decisions.
Limited to investors tracking CRISPR gene‑editing companies.
Counterpoint
Despite higher cash, the company’s expanding net loss could be viewed as a buying opportunity if the market overreacts.
Key entities
- companyIntellia Therapeutics
Nasdaq‑listed biotech developing CRISPR therapies.
- partnerRegeneron Pharmaceuticals
Collaboration partner on nex‑z program.
